feedback

Course Director

Joe O'Sullivan, MD, FRCPI, FFRRCSI, FRCR
Joe O'Sullivan, MD, FRCPI, FFRRCSI, FRCR

Centre for Cancer Research and
Cell Biology Queen's University Belfast
The Northern Ireland Cancer Centre
Belfast City Hospital
Belfast, Northern Ireland

Faculty

Neal Shore
Neal Shore, MD, FACS

Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina, USA

Accredited by

Oakstone Publishing, LLC

View Activity Materials

Activity Details

Credit Types:CME
Credit Amount:0.5 Credits
Release Date:2016-Dec-12
Expiration Date:2017-Dec-11
Estimated Time for Completion:30 minutes
Registration Required:No
Cost:Free of Charge

Funding Disclosure

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals.

Activity Description & Educational Objectives

In this activity, experts in metastatic castration-resistant prostate cancer (mCRPC) discuss the most recent data evaluating radionuclide therapy and its impact on haematologic safety.

Upon completion of this activity, participants should be better able to:

  • Review the mechanism of action of radiopharmaceutical therapies used to treat patients with mCRPC and bone metastases
  • Describe the long-term haematologic safety profile for a radionuclide therapy used in the treatment of mCRPC
  • Demonstrate how to individualise therapeutic strategies in order to optimise efficacy and minimise the risk of haematologic adverse events (AEs) when treating patients with mCRPC

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, radiation-oncologists, nuclear medicine specialists, and urologists involved in the management of patients with mCRPC.

Faculty & Disclosure / Conflict of Interest Policy

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Course Director and Interviewee

Professor Joe O'Sullivan, MD, FRCPI, FFRRCSI, FRCR
Professor of Radiation Oncology
Centre for Cancer Research and
Cell Biology Queen's University Belfast
Consultant Clinical Oncologist and
Clinical Lead for Radiotherapy
The Northern Ireland Cancer Centre
Belfast City Hospital
Belfast, Northern Ireland

Professor Joe O'Sullivan, MD, FRCPI, FFRRCSI, FRCR has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from: Bayer.
Speaker’s Bureau participant with: Astellas Pharma EMEA; Bayer; Janssen Pharmaceutical; and Sanofi.
Advisory Board for: Astellas Pharma EMEA; Bayer; Janssen Pharmaceutical; and Sanofi.

Interviewee

Neal Shore, MD, FACS
Medical Director, Carolina Urologic
Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina, USA

Neal Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:
Consultant for: AbbVie; Amgen Inc; Bayer AG; Dendreon; Ferring Pharmaceuticals; Medivation Inc; Roivant Sciences; and Tolmar Pharmaceuticals.
Grant/Research Support from: AbbVie.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labelled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabelled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and PeerVoice. Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 70% is needed.

Media: Internet
Release and Expiration Dates: December 12, 2016 - December 11, 2017
Time to Complete: 30 minutes

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerVoice or any of its supporters.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.